Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Urology
Published in: BMC Urology 1/2016

Open Access 01-12-2016 | Research article

Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson’s disease

Authors: Stephanie C. Knüpfer, Susanne A. Schneider, Mareike M. Averhoff, Carsten M. Naumann, Günther Deuschl, Klaus-Peter Jünemann, Moritz F. Hamann

Published in: BMC Urology | Issue 1/2016

Login to get access

Abstract

Background

To assess the efficacy and safety of intradetrusor onabotulinumtoxinA (OnabotA) injection treatment in patients with neurogenic lower urinary tract dysfunction (NLUTD), especially for patients with Parkinson disease (PD).

Methods

PD patients refractory to oral antimuscarinic participated in an off-label use study and were evaluated prior and after 200 IU OnabotA injection into detrusor muscle, including trigone. Changes due to treatment were evaluated using bladder diaries, urodynamics, and questionnaires. Statistical analysis comprised Wilcoxon rank-sum test. Values are presented as mean ± standard deviation.

Results

Ten PD patients (4 female and 6 male, mean age: 67.9 ± 5.36 years) with LUTD were enrolled. All patients tolerated the treatment. Bladder diary variables decreased significantly (p ≤ 0.011) after OnabotA injection compared to variables prior injection. Desire to void and maximum bladder capacity increased significantly in urodynamics (p ≤ 0.05). Maximum detrusor pressure during voiding phase normalised from 56.2 to 18.75 cm/H20. Detrusor overactivity was less often detectable. All patients voided spontaneously. Mean post void residual (PVR) volume was 77.0 ± 119.78 mL postoperatively. No urinary retention or side effects have been observed during/after treatment. Mean follow-up time was 4 months (range of 1–12). 4 patients requested repeated injection after a mean period of 10 months between first and second injection.

Conclusions

Our data confirm the efficacy and safety of 200 IU OnabotA injection in patients with neurogenic LUTD due to PD. The risk of urinary retention or high post-urinary residual volumes seems to be minor after OnabotA-injection. More research is needed with larger sample size to confirm the significance of these findings.

Trial registration

Trial Number: ISRCTN 11857462, Registration Date 2016/10/08
Literature
1.
Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, Aiyer LP. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009;103(3):4–11.CrossRefPubMed
2.
Chin-Chan M, Navarro-Yepes J, Quintanilla-Vega B. Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases. Front Cell Neurosci. 2015;9:124.CrossRefPubMedPubMedCentral
3.
Winge K, Fowler CJ. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord. 2006;21(6):737–45.CrossRefPubMed
4.
Ogawa T, Seki S, Masuda H, Igawa Y, Nishizawa O, Kuno S, Chancellor MB, De Groat WC, Yoshimura N. Dopaminergic mechanisms controlling urethral function in rats. Neurourol Urodyn. 2006;25(5):480–9.CrossRefPubMed
5.
Yoshimura N, Mizuta E, Kuno S, Sasa M, Yoshida O. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology. 1993;32(4):315–21.CrossRefPubMed
6.
Seki S, Igawa Y, Kaidoh K, Ishizuka O, Nishizawa O, Andersson KE. Role of dopamine D1 and D2 receptors in the micturition reflex in conscious rats. Neurourol Urodyn. 2001;20(1):105–13.CrossRefPubMed
7.
8.
Winge K, Werdelin LM, Nielsen KK, Stimpel H. Effects of dopaminergic treatment on bladder function in Parkinson’s disease. Neurourol Urodyn. 2004;23(7):689–96.CrossRefPubMed
9.
Pannek JBB, Castro-Diaz D, Del Popolo G, Groen J, Karsenty G, Kessler TM, Kramer G, Ströhrer M. EAU guidelines on neuro-urology. 2014.
10.
Kay GG, Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract. 2008;62(11):1792–800.CrossRefPubMedPubMedCentral
11.
Seif C, Herzog J, van der Horst C, Schrader B, Volkmann J, Deuschl G, Juenemann KP, Braun PM. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol. 2004;55(1):118–20.CrossRefPubMed
12.
Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131–9.CrossRefPubMed
13.
A AGaB. Neurophysiological effects of otulinumtoxin type A. Neurotox Res. 2006;9:109–14.CrossRef
14.
Anderson RU, Orenberg EK, Glowe P. OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson’s disease. Urology. 2014;83(1):22–7.CrossRefPubMed
15.
Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J Urol. 2009;182(4):1453–7.CrossRefPubMed
16.
17.
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–78.CrossRefPubMed
18.
Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, Cottenden A, Davila W, De Ridder D, Dmochowski R, Drake M, Dubeau C, Fry C, Hanno P, Smith JH, Herschorn S, Hosker G, Kelleher C, Koelbl H, Khoury S, Madoff R, Milsom I, Moore K, Newman D, Nitti V, Norton C, Nygaard I, Payne C, Smith A, Staskin D, et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010;29(1):213–40.CrossRefPubMed
19.
Abdel-Meguid T. Botulinum toxin A injections into neurogenic overactive bladder-to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol. 2010;184(6):2423–8.CrossRefPubMed
20.
Samal V, Mecl J, Sram J. Submucosal Administration of OnabotulinumtoxinA in the treatment of Neurogenic Detrusor Overactivity: Pilot Single-Centre Experience and Comparison with standard injection into the Detrusor. Urology International. 2013;91:423–8.CrossRef
21.
Kulaksizoglu H, Parman Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons’s disease. Parkinsonism Relat Disord. 2010;16(8):531–4.CrossRefPubMed
22.
Giannantoni A, Conte A, Proietti S, Giovannozzi S, Rossi A, Fabbrini G, Porena M, Berardelli A. Botulinum toxin type A in patients with Parkinson’s disease and refractory overactive bladder. J Urol. 2011;186(3):960–4.CrossRefPubMed
23.
Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results J Urol. 2000;164(1):692–7.CrossRefPubMed
24.
Mehnert U, Birzele J, Reuter K, Schurch B. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol. 2010;184(3):1011–6.CrossRefPubMed
25.
Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, Karsenty G, Schulte-Baukloh H, Schurch B, Wyndaele JJ. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009;55(1):100–19.CrossRefPubMed
26.
Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–50.CrossRefPubMed
27.
White WM, Pickens RB, Doggweiler R, Klein FA. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. J Urol. 2008;180(6):2522–6.CrossRefPubMed
28.
Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and Parkinson’s disease: urodynamic abnormalities and urinary symptoms. J Urol. 2000;164(5):1640–3.CrossRefPubMed
29.
Schurch B, Schmid DM, Stohrer M. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med. 2000;342(9):665.CrossRefPubMed
30.
Lucioni A, Rapp DE, Gong EM, Fedunok P, Bales GT. Intravesical botulinum type A toxin injection in patients with overactive bladder: Trigone versus trigone-sparing injection. Can J Urol. 2006;13(5):3291–5.PubMed
31.
Wüllner U, Standop J, Kaut O, Coenen V, Kalenka A, Wappler F. Parkinson’s disease. Perioperative management and anesthesia. Anaesthesist. 2012;61(2):97–105.CrossRefPubMed
32.
Roth B, Studer UE, Fowler CJ, Kessler TM. Benign prostatic obstruction and parkinson’s disease-should transurethral resection of the prostate be avoided? J Urol. 2009;181(5):2209–13.CrossRefPubMed
33.
Association WM. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.CrossRef
34.
Metadata
Title
Preserved micturition after intradetrusor onabotulinumtoxinA injection for treatment of neurogenic bladder dysfunction in Parkinson’s disease
Authors
Stephanie C. Knüpfer
Susanne A. Schneider
Mareike M. Averhoff
Carsten M. Naumann
Günther Deuschl
Klaus-Peter Jünemann
Moritz F. Hamann
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2016
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-016-0174-2

Other articles of this Issue 1/2016

BMC Urology 1/2016 Go to the issue

Research article

Pure retroperitoneal natural orifice translumenal endoscopic surgery (NOTES) transvaginal nephrectomy using standard laparoscopic instruments: a safety and feasibility study in a porcine model

Research article

A novel stepwise micro-TESE approach in non obstructive azoospermia

Research article

Global expression of AMACR transcripts predicts risk for prostate cancer – a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate

Research article

Determinants of peri-operative blood transfusion in a contemporary series of open prostatectomy for benign prostate hyperplasia

Research article

The efficacy and safety of silodosin for the treatment of ureteral stones: a systematic review and meta-analysis

Research article

Abiraterone acetate in metastatic castration-resistant prostate cancer – the unanticipated real-world clinical experience